Latest News

CBF listed on KTN’s Innovation Landscape for the Medicines Manufacturing Sector

Posted 09/12/2015

A new web portal (http://www.mmlandscape.ktn-uk.org/) was launched at the recent 12th Annual bioProcessUK Conference held in Cambridge on 25/6 November 2015. The portal developed by the Knowledge Transfer Network (KTN) on behalf of the Medicines Manufacturing Industry Partnership (MMIP) pulls together the innovation landscape, company base and ...

Good Luck, Phil!

Good Luck, Phil!

Posted 03/12/2015

Phil Angell-Manning, our Process Development Manager here at the CBF, will be representing England as part of Team GB in Hungary this weekend in the World Natural Team Competition. The competition focuses on strength and endurance across a variety of events and takes place in front of 5000 people in the city of Szekesfehervar. From all of us here ...

CBF features in Podcast "Vaccines - Concept to Clinic"

CBF features in Podcast "Vaccines - Concept to Clinic"

Posted 26/11/2015

In the latest episode of the Oxford Sparks podcast series on vaccines, our Operations Manager Emma Bolam talks about the processes involved in manufacturing a vaccine at the CBF.

The CBF Celebrates its 10th Birthday

The CBF Celebrates its 10th Birthday

Posted 02/11/2015

The Oxford University CLINICAL BIOMANUFACTURING FACILITY celebrates its 10 YEAR ANNIVERSARY today having manufactured and supplied materials for 50 clinical trials and certified over 62 products. This is a credit to the team of Scientists employed at the CBF supported by the JENNER INSTITUTE. So what holds for the next 10 years? - Planning ...

New vaccine manufactured by CBF aims to block transmission of malaria parasites

Posted 03/11/2015

The vaccine candidate, ChAd63 Pfs25-IMX313, was developed by researchers at the Jenner Institute and manufactured at the CBF in 2014 as part of the MultiMaxVax collaborative project, funded by the EU's 7th Framework Programme (FP7) and coordinated by the Jenner Institute. The adenovirus vaccine is composed of a transmission-blocking antigen from Plasmodium falciparum, the more dangerous form of malaria. The antigen is combined with Imaxio's pro-immunogenic technology IMX313, designed to increase immune responses, and two viral vectors, which are virus carriers modified to be harmless but which can transport the vaccine elements into the body's cells. One of those is a proprietary viral vector from Okairos (acquired by GSK in 2014).

Lemtrada (CAMPATH): a case study for UK bioscience success

Lemtrada (CAMPATH): a case study for UK bioscience success

Posted 15/07/2015

The UK BioIndustry Association (BIA) published their report "Celebrating UK Bioscience: unravelling the stories behind UK bioscience success" at their annual Parliament Day hosted on 25 June at the Houses of Parliament. In this report UK Business leaders are calling for a policy and funding environment that continues to support world-leading ...

CBF involved in further Ebola vaccine trial in Senegal

CBF involved in further Ebola vaccine trial in Senegal

Posted 17/07/2015

The CBF has labelled and certified further vials of ChAd3 and MVA vaccines for a Phase I Ebola vaccine trial in Dakar (Senegal). The trial is currently led by Pro Souleymane Mboup at the Laboratorie de Bacteriologie-Virologie in Senegal. The two trial vaccines were tested for the first time at the Jenner Institute in Oxford. The ChAd3 vaccine has ...

CBF Collaboration with HAV Vaccines Ltd. for Crohn's Disease Vaccine

CBF Collaboration with HAV Vaccines Ltd. for Crohn's Disease Vaccine

Posted 01/06/2015

The CBF has already undertaken Process Development work and will shortly be manufacturing the first adenovirus vaccine candidate for Crohn's disease. The vaccine is co-developed by Prof John Hermon-Taylor of HAV Vaccines Ltd. and Prof Sarah Gilbert of the Jenner institute. The vaccine is designed to contain antigens to Mycobacterium avium ...

CBF extension reaches next planning stage

CBF extension reaches next planning stage

Posted 28/05/2015

The University Capital Steering Committee have given approval for the CBF extension to progress to RIBA Work Stage C. The planned extension will give the CBF additional 470 m2 of space including two new cleanroom suites and fill & finish station to cope with the increasing demand to manufacture a variety of novel products (e.g. adenovirus ...

CBF importing and QP certifying further Ebola vaccines

CBF importing and QP certifying further Ebola vaccines

Posted 28/05/2015

The CBF have taken delivery of another batch of GSK's ChAd3-EBO Z vaccine and also imported the MVA-EBO Z vaccine manufactured at Emergent Biosolutions (US). Both vaccines were QP certified to trial at the CBF and are currently evaluated by Prof Adrian Hill in a Phase I trial in Oxford. Further trials using these and other vaccines (all to be QP ...